These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34409249)

  • 1. Use of sodium zirconium cyclosilicate for up-titration of renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure: a case series.
    Williams R; James A; Ashton M; Vaughan S; Wong A
    Eur Heart J Case Rep; 2021 Aug; 5(8):ytab281. PubMed ID: 34409249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study.
    Rastogi A; Pollack CV; Sánchez Lázaro IJ; Lesén E; Arnold M; Franzén S; Allum A; Hernández I; Murohara T; Kanda E
    Clin Kidney J; 2024 May; 17(5):sfae083. PubMed ID: 38699484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of a Bespoke Hyperkalaemia Clinic to Facilitate Prescribing of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction.
    Ali I; Green D; Kalra P; Kalra PA
    Cardiorenal Med; 2022; 12(5-6):196-204. PubMed ID: 36044877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
    Dwyer JP; Agiro A; Desai P; Oluwatosin Y
    Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
    Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New frontiers for management of hyperkalaemia: the emergence of novel agents.
    Nassif ME; Kosiborod M
    Eur Heart J Suppl; 2019 Feb; 21(Suppl A):A34-A40. PubMed ID: 30837803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia.
    Imamura T; Oshima A; Narang N; Kinugawa K
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy.
    Murphy D; Banerjee D
    Curr Heart Fail Rep; 2022 Aug; 19(4):191-199. PubMed ID: 35704263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of potassium-binder patiromer for up-titration of renin-angiotensin-aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report.
    Jiménez-Marrero S; Enjuanes C; Yun S; Comín-Colet J
    Eur Heart J Case Rep; 2020 Aug; 4(4):1-4. PubMed ID: 32974448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.
    Tardif JC; Rouleau J; Chertow GM; Al-Shurbaji A; Lisovskaja V; Gustavson S; Zhao Y; Bouabdallaoui N; Desai AS; Chernyavskiy A; Evsina M; Merkely B; McMurray JJV; Pfeffer MA
    ESC Heart Fail; 2023 Apr; 10(2):1066-1076. PubMed ID: 36564955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium/calcium polystyrene sulfonate.
    Onogi C; Watanabe Y; Tanaka A; Furuhashi K; Maruyama S
    Clin Kidney J; 2024 Feb; 17(2):sfae021. PubMed ID: 38404365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
    Silva-Cardoso J; Brito D; Frazão JM; Ferreira A; Bettencourt P; Branco P; Fonseca C
    Heart Fail Rev; 2021 Jul; 26(4):891-896. PubMed ID: 33599908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore.
    Chay J; Choo JCJ; Finkelstein EA
    Nephrology (Carlton); 2024 May; 29(5):278-287. PubMed ID: 38443742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
    Volterrani M; Perrone V; Sangiorgi D; Giacomini E; Iellamo F; Degli Esposti L;
    Eur J Heart Fail; 2020 Nov; 22(11):2049-2055. PubMed ID: 33459467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.